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Phospholipase C- (PLC-) is stimulated by epidermal
growth factor via activation of the epidermal growth
factor receptors. The PLC inhibitor, 3-nitrocoumarin (3-
NC), selectively inhibited PLC- in Madin-Darby canine
kidney cells without affecting the activity of PLC-. In
contrast, inhibitors of PLC-, hexadecylphosphocholine
and U73122, had no effect on the activity of PLC-. Inhi-
bition of PLC- by 3-NC was associated with an increase
in tight junction permeability across Madin-Darby ca-
nine kidney cell monolayers, as evidenced by 3-NC-in-
duced decrease in transepithelial electrical resistance
and increase in mannitol flux over a concentration
range that was inhibitory to PLC-. An analog of 3-NC,
7-hydroxy-3-NC (7-OH-3-NC), which was inactive as an
inhibitor of PLC-, also had no effect on tight junction
permeability. Treatment with 3-NC caused punctate dis-
ruption in the cortical actin filaments. The PLC- inhib-
itor, 3-NC, but not the inactive analog, 7-OH-3-NC,
caused hyperphosphorylation of the tight junction pro-
teins, occludin, ZO-1, and ZO-2. The serine/threonine ki-
nase inhibitor, staurosporine (50–200 nM), significantly
attenuated 3-NC-induced hyperphosphorylation of
ZO-2. This corresponded with attenuation by staurospo-
rine of 3-NC-induced increase in tight junction perme-
ability, suggesting a relationship between ZO-2 phos-
phorylation and tight junction permeability.
The concept of the epithelial tight junction as an imperme-
able barrier has undergone a marked change. Although the
rapidly evolving understanding about the architecture and
function of the tight junction is far from complete, it is clear
that the tight junction is a dynamic and complex multiprotein
structure, selectively permeable to certain hydrophilic mole-
cules, ions, and nutrients (1, 2).
The tight junction is a complex structure composed of both
transmembrane and cytosolic proteins (3, 4). Many signaling
pathways have been implicated in the regulation of tight junc-
tion permeability (e.g. tyrosine kinases, calcium, protein kinase
C) (5–8). Among the molecular events affected by signal trans-
duction along these pathways, leading to modulation of tight
junction permeability, are the phosphorylation status of certain
tight junction proteins and organization of actin filaments.
Many of the tight junction proteins (e.g. occludin, ZO-1, ZO-2,
and ZO-3) are phosphoproteins, and they may regulate tight
junction function by alteration of their phosphorylation status
(9–12). For example, phosphorylation of occludin is associated
with occludin localization and function at the tight junction in
Madin-Darby canine kidney (MDCK)1 cells (13), and increased
tyrosine phosphorylation of ZO-1 and ZO-2 is associated with
decreased transepithelial electrical resistance (TEER), induced
by treatment with a tyrosine phosphatase inhibitor (14). Fur-
thermore, displacement of ZO-1 accompanies the increased
tight junction permeability induced by this treatment (6).
In this study, we report that selective inhibition of phospho-
lipase C- (PLC-), an important class of signaling enzymes, by
3-nitrocoumarin (3-NC) (15) leads to increased tight junction
permeability across MDCK cell monolayers. Furthermore, our
results show that the mechanisms underlying the increased
tight junction permeability following inhibition of the two PLC
isozyme families,  and , are quite distinct. Thus, inhibition of
PLC-, unlike inhibition of PLC-, causes hyperphosphoryla-
tion of the tight junction proteins, ZO-1, ZO-2, and occludin.
EXPERIMENTAL PROCEDURES
Reagents—HEPES was obtained from Lineberger Comprehensive
Cancer Center (University of North Carolina at Chapel Hill). Hank’s
balanced salt solution was obtained from Mediatech (Herndon, VA).
Cell culture reagents were obtained from Invitrogen. Transwell™ in-
serts (12 wells/plate, 3-m pore and 1.0-cm2 area with polycarbonate or
polyester membrane) and plates (12-well) were obtained from Costar
(Cambridge, MA). [14C]mannitol and [3H]myo-inositol were obtained
from American Radiolabeled Chemicals (St. Louis, MO). AG1-X8 for-
mate columns were obtained from Bio-Rad. Anti-ZO-1, anti-ZO-2, anti-
occludin, rabbit IgG conjugated with horseradish peroxidase, tetra-
methylbenzidine single solution, and membrane blocking solution were
obtained from Zymed Laboratories Inc. (South San Francisco, CA).
NuPAGE™ 4–12% Bis-Tris gels, MOPS running buffer, NuPAGE™
transfer buffer, and nitrocellulose membranes were obtained from In-
vitrogen. Phalloidin conjugated with Texas Red™ was obtained from
Molecular Probes (Eugene, OR). Titanium tetrachloride (TiCl4), sali-
cylaldehyde, ethyl nitroacetate, and N-methylmorpholine were ob-
tained from Aldrich. All other compounds and reagents were obtained
from Sigma.
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Synthesis of 3-NC and 7-OH-3-NC—A procedure adapted from a
previously published method was used to synthesize 3-NC and 7-hy-
droxy-3-NC (7-OH-3-NC) (15). 1H NMR spectra for 3-NC and 7-OH-
3-NC were consistent with those reported (15).
Cell Culture—MDCK epithelial cell line strain II was obtained from
the American Type Culture Collection through the Lineberger Compre-
hensive Cancer Center (University of North Carolina at Chapel Hill).
MDCK cells, derived from normal proximal kidney epithelial cells of a
male cocker spaniel, which are a model for transport experiments (16),
were grown on Transwell™ inserts with polycarbonate membranes for
use in studies to determine the effect of absorption enhancers on TEER
and mannitol transport. The cells were grown on Transwell™ inserts
with transparent polyester membrane for use in confocal studies. Each
well was seeded with cells at a density of 100,000 cells/cm2. The cells
were then grown in cell medium (minimal essential medium supple-
mented with 10% fetal bovine serum, 0.1 mM non-essential amino acids,
100 units/ml penicillin, 100 g/ml streptomycin, and 0.2 g/ml ampho-
tericin B) and were maintained at 37 °C and 5% CO2. Confluent cells
were grown for 4 days when they differentiated into epithelial cell mono-
layers as evidenced by the establishment of a stable TEER between 150
and 250 ohmcm2 (EVOM epithelial tissue voltohmeter (World Precision
Instruments, Sarasota, FL) and an Endohm-12 electrode).
Determination of the Effect of 3-NC on TEER—Cell media were
aspirated from both apical and basolateral compartments of Tran-
swell™ inserts and replaced with 0.5 and 1.5 ml, respectively, of trans-
port buffer (Hank’s balanced salt solution supplemented with 10 mM
HEPES, pH 7.4). MDCK cell monolayers were then incubated at 37 °C
for 30 min, and TEER was measured. Experiments were initiated by
replacing the media in the apical compartment with transport buffer
containing 3-NC or vehicle. MDCK cell monolayers were incubated at
37 °C, and TEER values were measured after 30 min. Data from each
experiment were normalized to the response from the vehicle and were
reported as the mean  S.D. of three experiments (n  3) performed in
triplicate. The effect of 3-NC on TEER was evaluated at several con-
centrations, and the EC50 value, defined as the concentration that
caused a 50% decrease in TEER with respect to the untreated control
(17, 18), was determined.
Determination of the Effect of 3-NC on Mannitol Transport—Cell
media were aspirated from both compartments of Transwell™ inserts
and replaced with transport buffer. MDCK cell monolayers were then
incubated at 37 °C for 30 min. The integrity of the tight junctions of cell
monolayers was monitored with the measurement of TEER prior to the
experiment (150–250 ohmcm2). Transport experiments were initiated
by replacing the apical media with 0.5 ml of transport buffer containing
3-NC or vehicle and [14C]mannitol (55 mCi/mmol, 25 M). Transport
rates were monitored by quantifying the amount of [14C]mannitol ac-
cumulated (Packard Tri Carb 4000 Series liquid scintillation spectro-
photometer) in the basolateral side (1.5 ml) between a 30–60 min
interval after initiating the treatment. All transport experiments were
conducted under sink conditions (less than 10% of the total amount of
[14C]mannitol was present on the basolateral side at any given time).
The effect of 3-NC on the transport of [14C]mannitol was normalized to
that in the vehicle-treated cells and was reported as the mean  S.D. of
three experiments (n  3) performed in triplicate. The EC10, defined as
the concentration of 3-NC that causes a 10-fold increase in mannitol
flux with respect to the vehicle-treated control (17, 18), was determined
from plots of mannitol flux versus 3-NC concentrations.
Determination of PLC Activity and Its Inhibition by Cellular Assay—
The activity of PLC- and - in MDCK cells was determined by adap-
tation of a previously published method (19). MDCK cells were seeded
at 400,000 cells/well in a 12-well plate and subsequently cultured for 4
days. The cell monolayers were then labeled with [3H]myo-inositol (1.6
Ci/well in 0.4 ml of inositol-free media) for 24 h at 37 °C. The inhibitor,
3-NC, was added at different concentrations to the media, and the cells
were incubated for 30 min at 37 °C. Assays for PLC activity were
initiated on labeled cells that were removed from the incubator by
immediately supplementing the cells with 100 l of 250 mM HEPES (pH
7.3), containing 100 mM LiCl with epidermal growth factor (EGF) (final
concentration: 20 ng/ml) or ATP (final concentration: 100 M), which
was added to stimulate PLC- or - activity, respectively. The cells were
then incubated at 37 °C for 15 min to allow accumulation of [3H]inositol
phosphates. Incubations were terminated by aspiration of the media
and the addition of 1 ml of boiling 10 mM EDTA (pH 8.0). The super-
natant was applied to AG1-X8 formate columns for chromatographic
isolation of [3H]inositol phosphates (20). The amount of [3H]inositol
phosphates was measured by liquid scintillation counting in a Packard
Tri Carb 4000 Series spectrometer. Data from each experiment were
normalized to the response observed with 20 ng/ml EGF or 100 M ATP
for PLC- or - activity, respectively, and were reported as the mean 
S.D. of three experiments (n  3) performed in triplicate. Inhibition of
PLC- or - activity by the respective inhibitors was determined by
incubation of the cells with the inhibitors at indicated concentrations
for 30 min prior to assaying for the enzyme activity and comparing the
enzyme activity so determined with the enzyme activity in untreated
control cells. The IC50 (PLC), defined as the concentration of 3-NC that
causes a 50% decrease in EGF-stimulated PLC- activity (accumulation
of [3H]inositol phosphates), was determined from plots of PLC- activity
versus 3-NC concentration. The cell viability upon the inhibition treat-
ment was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assay (21), also known as the MTT assay.
Determination of the ZO-1 and ZO-2 Phosphorylation Status by Au-
toradiography—MDCK cells were incubated in phosphate-free medium
for 60 min at 37 °C. [32P]orthophosphate (1.0 mCi) was added to each
flask and incubated for 2 h at 37 °C. 3-NC (PLC- inhibition) was added
to media at different concentrations, and cells were incubated for 30
min at 37 °C. The media were removed, and 1.5 ml of lysis buffer
containing 20 mM Tris (pH 7.5), 2 mM EDTA, 137 mM NaCl, 1% Triton
X-100, 10% glycerol with phosphatase and protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1 mM sodium vanadate, 10 g/ml leu-
peptin, 0.2 M microcystin) were added to each flask. The flasks were
then incubated for 1 h at 4 °C. Lysis buffer was transferred into 1.7-ml
centrifuge tubes. Agarose-protein A (40 l) was added to each tube.
Tubes were tumbled for 40 min at 4 °C and centrifuged at 15,000 rpm
for 1 min. Supernatant was retained and transferred into new 1.7-ml
centrifuge tubes, and precipitate was discarded. Anti-ZO-1 or anti-ZO-2
(1 g) was added to each tube, and the tubes were tumbled for 120 min
at 4 °C. Agarose-protein A (40 l) was added to the tubes with anti-ZO-1
or anti-ZO-2, and the tubes were tumbled for 40 min at 4 °C and then
centrifuged at 15,000 rpm for 1 min. Supernatant was discarded, and
the immunoprecipitate was washed four times with lysis buffer. SDS
gel-loading buffer (40 l) containing 50 mM Tris-Cl (pH 6.8), 100 mM
dithiothreitol, 2% SDS, 0.1% bromphenol blue, and 10% glycerol was
added to each tube. Tubes were incubated for 4 min at 75 °C in a dry
bath incubator, cooled on ice for 5 min, and centrifuged at 15,000 rpm
for 1 min. Samples were subjected to SDS-PAGE. The gels were stained
and fixed with colloidal blue in 10% methanol and subsequently dried
and exposed to Fuji Medical x-ray Film at 80 °C.
Determination of the Occludin Phosphorylation Status by Western
Blotting—MDCK cell monolayers were treated with 3-NC, and occludin
was immunoprecipitated with anti-occludin (1 g) by a procedure iden-
tical to that described above. Proteins in the immunoprecipitate were
separated on NuPAGE™ 4–12% Bis-Tris gels and subsequently trans-
ferred to a nitrocellulose membrane. The membrane was incubated with
membrane blocking solution overnight at 4 °C, incubated with anti-occlu-
din (1 g/ml) for 1 h at room temperature, and then washed with PBS. The
membrane was further incubated with goat anti-rabbit IgG, conjugated
with horseradish peroxidase for 40 min at room temperature, and then
washed with PBS. Tetramethylbenzidine Single solution was then incu-
bated with the membrane until protein bands were visible.
Determination of Actin Organization with Phalloidin—Cell media
were aspirated from both apical and basolateral compartments of
Transwell™ inserts with transparent polyester membrane and re-
placed with transport buffer. MDCK cell monolayers were then incu-
bated at 37 °C for 30 min, and TEER of each cell monolayer was
measured. Transport buffer containing 3-NC or vehicle was added to
the apical side of these cells. The cell monolayers were incubated at
37 °C, and TEER values were measured after 30 min. Transport buffer
was replaced with phalloidin conjugated with Texas Red™ (final con-
centration: 200 nM) in 3.7% formaldehyde (0.2 ml), incubated for 30 min
at 4 °C, and subsequently washed with transport buffer. Actin filament
organization was viewed with Zeiss LSM-410 inverted laser scanning
microscope (Carl Zeiss, Oberkochen, Germany), fitted with a 100
objective. Several vertical sections (x–z) of the cell monolayers were
taken to define the top and bottom of this cell monolayer. En face
sections (x and y) were then selected from the cortical (mid-cell) sections
of the cell monolayers.
Data Analysis—The Student’s t test for unpaired data was used to
determine significant differences (p  0.05) between the mean  S.D.
from untreated and treated MDCK cell monolayers.
RESULTS
PLC- Activity in MDCK Cell—EGF, which has been known
to activate PLC- via the EFG receptors (22), stimulated PLC-
activity in MDCK cells, as evidenced by a 3-fold increase in
Regulation of Tight Junction Permeability by PLC- 35761
[3H]inositol phosphates over the basal levels in the prelabeled
cells. These results established the presence of PLC- in MDCK
cells. Both U73122 and HPC, known inhibitors of PLC-,2
inhibited ATP-stimulated PLC- activity but had no effect on
the PLC activity that was stimulated by EGF (Fig. 1). In
contrast, 3-NC (see Fig. 2 for structure), a known inhibitor of
PLC- (15), inhibited EGF-stimulated PLC activity in MDCK
cells (30-min treatment) without affecting the ATP-stimulated
PLC- activity (Fig. 1).
Inhibition of PLC- and Enhancement of Tight Junction
Permeability by 3-NC—The selective PLC- inhibitor, 3-NC
(15), inhibited the EGF-stimulated PLC- activity in MDCK
cell monolayers in a concentration-dependent manner (Fig. 3).
IC50 (PLC), the concentration of 3-NC that inhibited EGF-stim-
ulated PLC- activity by 50%, was 18  1 M. Interestingly,
3-NC also decreased TEER, a measure of tight junction perme-
ability, across MDCK cell monolayers in a concentration-de-
pendent manner (Fig. 3), and the relationship between de-
crease in TEER and concentration was very similar to that
between decrease in PLC activity and concentration. Further-
more, mannitol flux, which is yet another measure of tight
junction permeability, increased progressively when MDCK
cell monolayers were treated with increasing concentration of
3-NC on the apical side (Fig. 3). The relationship between 3-NC
concentration and increase in mannitol flux corresponded well
with the concentration/TEER and concentration/PLC activity
relationships (Fig. 3). EC50 (the concentration of 3-NC that
decreases TEER by 50%) and EC10 (the concentration of 3-NC
that increases mannitol flux by 10-fold) were determined from2 P. D. Ward, H. Ouyang, and D. R. Thakker, unpublished results.
FIG. 1. The selectivity of 3-NC, HPC, and U73122 for inhibition
of PLC- and -. MDCK cell monolayers were labeled with [3H]myo-
inositol for 24 h at 37 °C. The effect of the test compounds on PLC- and
- activity, stimulated with 100 M ATP or 20 ng/ml EGF, respectively,
was determined by a 30-min incubation with the cells as described
under “Experimental Procedures.” Data points represent mean  S.D.
(n  3). The clear bar represents EGF-stimulated PLC- activity, and
the shaded bar represents ATP-stimulated PLC- activity.
FIG. 2. Structure of the PLC- inhibitor, 3-NC, and its inactive
analog, 7-OH-3-NC.
FIG. 3. The effect of 3-NC on TEER, EGF-stimulated PLC-
activity, and mannitol flux in MDCK cells. TEER was measured
after a 30-min incubation with different concentrations of 3-NC at
37 °C. PLC- activity was measured as described under “Experimental
Procedures.” To determine the effect of 3-NC on mannitol flux,
[14C]mannitol and 3-NC were applied apically, and the amount of
[14C]mannitol that accumulated in the basolateral side between 30 and
60 min post-treatment (3-NC or vehicle) was quantified.
FIG. 4. The effect of 3-NC on actin filament organization in
MDCK cell monolayers. The cells were treated apically with 3-NC for
30 min at 37 °C; TEER was measured before and after treatment. Cell
monolayers were then incubated with phalloidin-conjugated with Texas
Red in 3.7% formaldehyde for 30 min at 4 °C and subsequently washed
with transport buffer. Actin filament organization was viewed with
Zeiss confocal microscope. Bar  15 m.
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these relationships, and these values were 24  1 and 34  5
M, respectively. A close structural analog of 3-NC, 7-OH-3-NC
(Fig. 2), which was reported to be inactive as an inhibitor of
PLC- (15), had no effect on either PLC activity or tight junc-
tion permeability across MDCK cell monolayers at a concen-
tration (500 M) that represented 25-fold the IC50 (PLC) of
3-NC (data not shown). Taken together, these results suggest
that inhibition of PLC- is associated with an increase in tight
junction permeability across MDCK cell monolayers. It is im-
portant to note that in the experiments performed to determine
the effect of 3-NC on the enzyme activity as well as on TEER
and mannitol transport, the cell viability was not compromised
as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assay, also known as the MTT assay
(21).
Relationship between PLC- Inhibition and Actin Filament
Organization—We have observed that inhibition of PLC- with
U73122 leads to disorganization of actin filaments in the cor-
tical region (mid-cell region) of MDCK cells.2 To determine
whether inhibition of PLC- has a similar effect, MDCK cell
monolayers were treated with 3-NC at a concentration that
caused a significant increase in tight junction permeability and
inhibition of PLC- (30 M). Treatment with 3-NC appeared to
have induced punctate disruption in cortical actin as the cor-
tical actin on the cell border appeared more discontinuous than
in untreated cell monolayers (Fig. 4). This result suggests that
3-NC might cause changes in the interactions of actin filaments
with the proteins in the junctional complexes.
Relationship between Inhibition of PLC- and Tight Junction
Protein Phosphorylation—Fig. 5A depicts the phosphoryla-
tion status of three tight junction proteins, ZO-1, ZO-2, and
occludin, in response to the treatment of MDCK cell mono-
layers with 3-NC. The phosphorylation status of ZO-1 and
ZO-2 was determined by autoradiography of the immunopre-
cipitated proteins from 32P-labeled cells. Whereas the phos-
phorylation status of occludin was determined by assessing
the relative intensity of hyperphosphorylated 73-kDa occlu-
din bands and hypophosphorylated 66-kDa occludin bands
(electrophoretic separation and Western blot) by the method
of Wong (13).
At a concentration that causes significant inhibition of
PLC- and increase in tight junction permeability (30 M),
3-NC caused hyperphosphorylation of ZO-1 and ZO-2 as evi-
denced by a significant increase (over control) in the intensity
of the 32P bands at 210 and 160 kDa, respectively. Hyperphos-
phorylation of occludin by this treatment was also apparent
from an increase in the intensity of the 73-kDa band and a
decrease in the intensity of the 66-kDa band with respect to the
vehicle-treated control (Fig. 5A). At a lower concentration (5
M) that is ineffective in causing PLC inhibition or increased
tight junction permeability, 3-NC did not affect phosphoryla-
tion status of ZO-2 or occludin; however, phosphorylation of
ZO-1 was increased with respect to control. Interestingly, the
3-NC analog, 7-OH-3-NC, which does not inhibit PLC- (15) or
increase tight junction permeability, was significantly less ef-
fective than 3-NC in causing an increase in ZO-2 phosphoryl-
ation and had negligible effect on occludin phosphorylation
(Fig. 5B). These results suggest that hyperphosphorylation of
selected tight junction proteins may be an important step when
the tight junction permeability is increased in response to
PLC- inhibition.
To further investigate the relationship between hyperphos-
phorylation of these proteins by the PLC- inhibitor 3-NC
and tight junction permeability across MDCK cell monolay-
ers, the effect of kinase inhibitors on these events was deter-
FIG. 5. The effect of 3-NC on the phosphorylation state of ZO-1,
ZO-2, and occludin: the effect of 3-NC (A) and the effect of
7-OH-3-NC (B), an inactive structural analog of 3-NC. For deter-
mination of ZO-1 and ZO-2 phosphorylation status, 32P-labeled MDCK
cells were treated with the test compound or vehicle (Control) for 30
min. ZO-1 or ZO-2 was immunoprecipitated, subjected to PAGE,
stained with colloidal blue, and exposed to Fuji medical x-ray film at
80 °C. Protein levels of ZO-1 and ZO-2 for each treatment were sim-
ilar. For determination of occludin phosphorylation status, MDCK cells
were treated with the test compound or vehicle (Control) for 30 min.
Occludin was immunoprecipitated and loaded onto a NuPAGE 4–12%
Bis-Tris gel, transferred to a nitrocellulose membrane, and incubated
with anti-occludin. Subsequently, membranes were incubated with goat
anti-rabbit IgG conjugated to horseradish peroxidase. Tetramethylben-
zidine single solution was added to develop bands.
FIG. 6. Co-ordinate attenuation by staurosporine (Stauro) of
3-NC-induced hyperphosphorylation of ZO-2 (A) and increase in
tight junction permeability (B). For the phosphorylation experi-
ment, 32P-labeled MDCK cells were treated with staurosporine (200 nM,
maximal effect on TEER (B)) for 1 h at 37 °C. Test compound (30 M) or
vehicle was added, and cells were incubated for 30 min at 37 °C. Phos-
phorylation status of ZO-2 was determined as described in Fig. 5.
Protein levels of ZO-2 for each treatment were similar. For the TEER
experiment, different concentrations of staurosporine were applied api-
cally and incubated for 1 h at 37 °C. MDCK cell monolayers were
washed with transport buffer, and 3-NC (30 M) was applied apically.
TEER was measured after a 30-min incubation with the test compound
at 37 °C.
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mined. Tyrosine kinase inhibitors, tyrphostin-25 (24) and
genestein (25), had a negligible effect on the 3-NC-induced
changes in tight junction protein phosphorylation or perme-
ability (data not shown). On the other hand, the serine/
threonine kinase inhibitor, staurosporine (26), significantly
attenuated the 3-NC-induced (i) hyperphosphorylation of
ZO-2 (Fig. 6A) and (ii) increased tight junction permeability
(Fig. 6B). Staurosporine had no effect, however, on 3-NC-
induced hyperphosphorylation of occludin (data not shown).
These results suggest that 3-NC-induced hyperphosphoryla-
tion of ZO-2 in MDCK cells is mediated by a serine/threonine
kinase. Unlike 3-NC, the PLC- inhibitors, U73122 and HPC,
did not increase ZO-2 or occludin phosphorylation (data not
shown), indicating that PLC- inhibition does not cause a
change in the phosphorylation state of these tight junction
proteins.
DISCUSSION
In the present study, we demonstrate that selective inhibi-
tion of PLC- leads to increased tight junction permeability,
presumably via hyperphosphorylation of selected tight junction
proteins. In contrast to the selective PLC- inhibitor, U73122
(27, 28), which caused a marked disruption of actin filaments
without causing a change in phosphorylation state of ZO-2 or
occludin,2 the PLC- inhibitor 3-NC (15) caused hyperphospho-
rylation of the tight junction proteins ZO-1, ZO-2, and occludin.
It is important to note that hyperphosphorylation of ZO-2 and
occludin is caused by 3-NC at concentrations that are entirely
consistent with its potency as an inhibitor of PLC- and en-
hancer of tight junction permeability. The serine-threonine
kinase inhibitor staurosporine attenuated 3-NC-induced (i) hy-
perphosphorylation of ZO-2 and (ii) increase in tight junction
permeability across MDCK cell monolayers. These results pro-
vide strong support to the hypothesis that hyperphosphoryla-
tion of ZO-2 plays a role in increasing the tight junction per-
meability across epithelial tissues as exemplified by MDCK cell
monolayers. Since hyperphosphorylation of ZO-1 occurs at a
concentration of 3-NC that does not cause significant inhibition
of PLC-, the association between PLC- inhibition and ZO-1
hyperphosphorylation is somewhat tenuous. However, it is not
inconceivable that the extent of hyperphosphorylation caused
at suboptimal concentration may not be sufficient to affect
sufficient changes in the tight junction structure to cause an
observable drop in permeability. Alternatively, 3-NC may
cause hyperphosphorylation of a site at a low concentration
that is not involved in alteration of the tight junction perme-
ability. A cause-and-effect relationship between phosphoryla-
tion of tight junction proteins and increase in tight junction
permeability has not been established previously, although
some evidence for this does exist. For example, phosphorylation
of occludin is associated with reduced tight junction barrier
function and assembly in MDCK cell monolayers (13, 29, 30).
As with occludin, phosphorylation of ZO-2 has been implicated
in reduced efficacy of the tight junction barrier (31–33); for
example, the drop in TEER after temperature shift in temper-
ature-sensitive v-src MDCK cells is associated with hyperphos-
phorylation of ZO-2 (33).
The PLC-dependent pathway is initiated when PLC hydro-
lyzes phosphatidylinositol 4,5-bisphosphate into two intracel-
lular products: diacylglycerol and inositol 1,4,5-triphosphate.
Inositol 1,4,5-triphosphate is released into the cytosol and in-
duces Ca2 release from the endoplasmic reticulum (20, 34).
Increased levels of diacylglycerol, alone or in conjunction with
Ca2, activate the novel and conventional protein kinase C
isozymes (35–37). Thus, PLC appears to play a regulatory role
by affecting protein kinase C-mediated alteration of the phos-
phorylation state of the target proteins. The results in the
present study, i.e. hyperphosphorylation of the tight junction
proteins following inhibition of PLC-, are counterintuitive
but consistent with the results obtained in other laboratories.
For example, activation of protein kinase C by the phorbol
ester, 12-O-tetradecanoylphorbol 13-acetate, leads to dephos-
phorylation of occludin in LLC-PK1 cell monolayers (23).
These results suggest that other intervening steps must exist
between modulation of the activity of a protein kinase C
isozyme and hyperphosphorylation of the tight junction
proteins.
In conclusion, the results in this study provide strong evi-
dence for a role of PLC- in the regulation of epithelial tight
junction permeability. Besides establishing a relationship be-
tween the catalytic activity of the enzyme and the tight junc-
tion permeability, the results show that the changes in the PLC
activity lead to changes in the phosphorylation state of some of
the tight junction proteins. The inverse relationship between
PLC- activity and the phosphorylation state of these proteins
suggests the intervention of more than one kinase. The eluci-
dation of events leading to the changes in the phosphorylation
state of tight junction proteins following inhibition of PLC-
will provide more definitive insights into the role of this PLC
isozyme in regulation of the structure and function of the tight
junction in epithelial tissue.
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